SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Cannabis >

Lexaria Bioscience Corp. (LXRP)

Add LXRP Price Alert      Hide Sticky   Hide Intro
Moderator: The_Free_Nebula, stockman69, Fallingknife75, MasterBidder
Search This Board: 
Last Post: 5/26/2017 9:17:26 AM - Followers: 153 - Board type: Free - Posts Today: 1   
Recent news

New ViPova Products Introduced


Kelowna, BC / August 12, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (the “Company”) is pleased to announce a suite of new ViPovaTM products available for purchase immediately. The new products all utilize Lexaria’s patent-pending technology designed to enhance bioavailability.

In addition to the new products listed below, Lexaria is pleased to announce that ViPovaTM brand coffee and hot chocolate are expected to be available in September; and that the much-anticipated Lexaria Energy protein bar is expected to be available around the end of September, in two initial flavors. More information on these products will be released as available.

Among the highest selling tea categories in the world are Black, De-Caf, Green, and Earl Gray – and Lexaria is pleased to inform its stakeholders that with today’s announcement, we now offer teas in most of the worlds favored categories. This is an additional important step in delivering the superfood goodness of hemp through popular foods.

The new ViPovaTM brand teas that are now available are:

Earl Gray Tea

Rich Bergamot flavored broken orange pekoe and infused hemp oil. The distinctive citrus flavor comes from the oil extracted from the rind of the bergamont orange, a small citrus tree grown mostly in Italy. For those craving something more exotic, try “London Fog” comprised of ViPovaTM Earl Gray tea, steamed milk and a touch of vanilla.

Herbal Cherry Black Tea

Fruity, sweet cherry and safflower combined with black tea and hemp oil. With the traditional caffeine content of black tea, this is a bright and flavorful pick-me-up in the morning or mid day. Delicious.

Low-Caf Organic Evening Green Tea

Blended organic green teas and rich hemp oil with a nutty flavor and reddish-gold appearance. Low in caffeine, ViPovaTM Evening Green Tea is perfect as a calming, soothing brew in the afternoon and evening, and only ViPovaTM brand Evening Green Tea contains hemp oil specially formulated for enhanced absorption.

De-Caf English Breakfast Tea

A smooth, traditional broken orange pekoe modernized with our patent-pending hemp oil infusion. You may have tried orange pekoe before, but nowhere else will you find our patent pending formula. Naturally de-caffeinated, you can enjoy this day and night while experiencing hemp’s superfood qualities.

Herbal Masala Chai Tea

ViPovaTM has developed unique spiced tea formulations you simply cannot find anywhere else! A sweet & spicy blend of rooibos, ginger, cinnamon, cardamom, vanilla, and hemp oils. Rooibos contains polyphenols and is high in ascorbic acid. Naturally free of caffeine, this wonderful blend can be enjoyed any time of day or evening.

Herbal Bengal Chai Tea

Our most complex blend of rooibos, pepper, cloves, ginger, cinnamon, cardamom, vanilla and hemp oils. Rooibos is caffeine-free, does contain polyphenols and is naturally high in ascorbic acid. The cinnamon and vanilla make it sweet, but you’ll appreciate its spicy side too.

All the teas listed above are in stock now and available for immediate shipping directly to consumers at just $24 for 8-bag packs, with incentives for larger quantities. Wholesalers are always welcome to make contact to discuss commercial terms. Order at

The new tea flavors join the existing two tea lines – ViPovaTM Starter and ViPovaTM Original Yunnan Black – to now offer consumers a total of 8 different ViPovaTM tea experiences. ViPova Starter 4-bag tea packs are an entry-level product with our lowest price to the consumer at just $10.

Lexaria believes the greatly expanded line of tea flavors and recent lower pricing will together combine to offer consumers their most compelling options in the marketplace today, for flavorful foods delivering the goodness of hemp oil compounds. Together with the ever expanding number of online and traditional locations to buy the products, Lexaria believes it is on the cusp of a meaningful increase in sales revenues.

Lexaria also points out the balanced offering of caffeinated and de-caffeinated products. Containing caffeine are the VipovaTM Starter; ViPovaTM Original Yunnan; Earl Gray; Herbal Cherry; and Low-caf Evening Green. Free of caffeine are the English Breakfast; Masala Chai; and Bengal Chai.

Seperately, Lexaria also announces that it has signed a license agreement with 51%-owned subsidiary PoViva Tea LLC, formalizing and granting Lexaria a 35-year worldwide license to use and re-license the patent-pending technology covered under four different US Provisional Patent Applications, one US Utility Patent Application, and one PCT Patent Application.

Lexaria’s technology is designed to allow for higher bioavailability rates for THC and for CBD than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria’s innovative lipid formulation process is designed to allow the delivery of molecules such as are contained within hemp oil without the harmful side effects of ingestion via smoking, and should be embraced for the benefits to public health.

About Lexaria

Lexaria is a food sciences company focused on the delivery of hemp oil compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technologies.

About ViPovaTM

ViPovaTM uses only legal hemp oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its patent-pending process to infuse concentrated amounts of hemp oil within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPovaTM has this ground-breaking technology for hemp oil/lipid infusion.

Lexaria Files U.S. Utility and International Patent Applications Encompassing Expanded Uses for Its Core Technology

Natural vitamin pills. Alternative medicine.

Kelowna, BC / June 11, 2015 / Lexaria, Corp. (OTCQB:LXRP) (CSE:LXX) (“Lexaria” or the “Company”) provides the following information regarding existing and new patents pending.

Lexaria has initiated the simultaneous filing of a U.S. utility patent application and an International patent application under the Patent Cooperation Treaty (PCT) procedure, both at the U.S. Patent and Trademark Office. These applications follow the Company’s 2014 and 2015 family of provisional patent application filings in the U.S. and serve two additional broad purposes:

  1. Lexaria is seeking protection of its intellectual property under international treaties. To this end Lexaria has filed for PCT patent application protection. There are 148 countries that are signatories to the Patent Cooperation Treaty, including such major markets as Canada, China, India, much of Europe and the Middle East, the United Kingdom and Japan among others.
    Lexaria believes its lipid infusion technology has applications beyond the delivery of just cannabinoids. Based on further formulation testing, Lexaria has included additional lipophilic molecules that may be delivered via food and beverage formats utilizing its technology, widely encompassing three major new market opportunities for the Company: Nicotine; Nonsteroidal Anti-Inflammatories (NSAIDs); and Vitamins.

Lexaria notes that although additional testing and examination of these formulations is planned prior to any potential market introduction for these three new market opportunities, the Company owes a fiduciary duty to its shareholders to protect the intellectual property associated with its inventions. Since the relevance of this technology has the potential to be markedly material, the Company is of the view that reporting these developments is warranted.  Additional details are provided below, and further information will be provided in the future.


“Our technology opens up whole new avenues for delivering numerous bioactive compounds of interest into the body as part of anyone’s normal diet,” said John Docherty, President.  “We believe that consumer demand could be enormous for these new product formats because they could offer both high bioavailability and a safe and naturally formulated alternative relative to their conventional predecessors.”



When Lexaria first began examining the legal medical cannabis market in 2013, and entered the market in 2014, the Company believed it could make an impact in perhaps both the Canadian and U.S. marketplaces. Our pursuit and development of technology has expanded our potential area of impact, both geographically and by sector. Because of the applicability of our technology to markets outside of the legal cannabis sector, we have taken the necessary steps to protect that intellectual property within larger global markets, regardless of whether they lie within the medical cannabis sector or in other unrelated sectors.



NICOTINE. More than 99% of all nicotine that is consumed worldwide is delivered through smoking cigarettes. Approximately 6,000,000 deaths per year, worldwide, are attributed primarily to the delivery of nicotine through the act of smoking according to the Centers for Disease Control and Prevention, which also estimates that over $170 billion per year is spent just in the USA on direct medical care costs for adult smokers. 69% of U.S. adult smokers want to quit smoking and 43% of US adult smokers have attempted to quit in any twelve month period.

Worldwide, retail cigarette sales were worth $722 billion in 2013, with over 5.7 trillion cigarettes sold to more than 1 billion smokers.

RELEVANCE: Lexaria postulates that delivery of nicotine to satisfy current demand, utilizing our patent pending lipid-delivery technology in common food groups, could shift demand from smoking cigarettes to alternative nicotine-based food products. Since most of the adverse health outcomes of nicotine consumption are associated with the delivery method and only to a lesser degree to the actual ingestion of nicotine, there could be a vast positive community health outcome through the reduction in smoking cigarettes. Additional research and regulatory compliant investigations would need to be conducted before otherwise healthy foods such as tea, coffee or energy bar snacks containing nicotine could be introduced. Nicotine is a named molecule in the latest Lexaria patent applications.


NSAID. Nonsteroidal Anti-inflammatories are the second-largest category of pain management treatment options in the world. The global pain management market was estimated at $22 billion in 2011, with $5.4 billion of this market being served by NSAID’s. The U.S. makes up over one-half of the global market. The opiods market (such as morphine) form the largest single pain management sector but are known to be associated with serious dependence and tolerance issues.

Some of the most commonly known NSAIDs are ASA (Aspirin), Ibruprofen (Advil, Motrin), and Acetaminophen (Tylenol). (Acetaminophen is not accepted by all persons to be an NSAID.) Although NSAIDs are generally a safe and effective treatment method for pain, they have been associated with a number of gastrointestinal problems including dyspepsia and gastric bleeding.

RELEVANCE:  Lexaria postulates that delivery of NSAIDs through a lipid-based mechanism could provide the beneficial properties of pain relief with lessened negative gastrointestinal effects, and also potentially deliver lower dosages of active ingredients with similar pain management outcomes as current pill forms at higher dosages. ASA, Piroxicam, Diclofenac, Indomethacin, Ibruprofen, and Acetaminophen are all named molecules in the latest Lexaria patent applications.


VITAMINS. The global vitamin and supplement market is worth $68 billion according to Euromonitor. The category is both broad and deep, comprised of many popular and some lesser known substances. Vitamins in general are thought to be an $8.5 billion annual market in the U.S. The U.S. is the largest single national market in the world, and China and Japan are the 2nd and 3rd largest vitamin markets.

Vitamin E is fat soluble and can be incorporated into cell membranes which can protect them from oxidative damage. Global consumption of natural source vitamin E was 10,900 metric tons in 2013 worth $611.9 million.

RELEVANCE:   Lexaria postulates that delivery of fat soluble vitamins through its patent-pending lipid-based delivery mechanism may result in less waste and lower dosages required than most current pill forms. As well, ingestion of pills is an unpleasant experience for many people so it is possible that vitamin delivery through common food groups could vastly expand market demand for this sector. Vitamin E is a named molecule in the latest Lexaria patent applications.


“Lexaria’s groundbreaking new technology offers a new way of delivering active ingredients. Not only are there a number of important benefits associated with higher absorption rates of beneficial ingredients, but there is a crucial public health benefit associated with any reduction in cigarette or cannabis smoking,” said Chris Bunka, CEO of Lexaria. “I am incredibly proud of the Lexaria team as we continue to investigate whether we have found the first viable alternative to smoking.”

Lexaria is increasingly focused on its pursuit of intellectual property and an expanding portfolio of patent pending applications. The Company continues to work on introducing an expanding variety of consumer food products which remains on target for 2015 delivery.


About Lexaria

Lexaria is a food sciences company focused on the delivery of cannabinoid compounds procured from legal, agricultural hemp, through gourmet foods based upon its proprietary infusion technologies.

About ViPovaTM

ViPovaTM uses only legal CBD oil extracts, grown from agricultural hemp in locations where it is legal to do so, in ViPovaTM-branded tea. ViPovaTM uses its patent-pending process to infuse concentrated amounts of CBD within lipids in its tea, providing more bioactivity and comfort to the body during the absorption process. Only ViPovaTM has this ground-breaking technology for CBD/lipid infusion.


Share structure as of August 9, 2015:

Outstanding Shares 39,932,984 a/o Aug 09, 2015
CEO has accumulated 9.5M shares to date  see latest Form 4 from 8/13/15



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
LXRP News: Current Report Filing (8-k) 05/23/2017 05:17:59 PM
LXRP News: Current Report Filing (8-k) 05/12/2017 03:44:53 PM
LXRP News: Current Report Filing (8-k) 05/09/2017 06:03:58 AM
LXRP News: Current Report Filing (8-k) 05/04/2017 01:19:37 PM
LXRP News: Current Report Filing (8-k) 04/28/2017 06:06:56 AM
#15286  Sticky Note LXRP - Daily & Weekly Charts The_Free_Nebula 01/27/17 11:13:12 AM
#15257  Sticky Note Podcast highlights (with link to podcast) Goals for 2017: moparfan 01/26/17 12:22:42 PM
#14346  Sticky Note LXRP has free real time L2 available at MasterBidder 12/02/16 03:15:44 PM
#13701  Sticky Note Check out this trademark for $LXRP....seems we have stockman69 10/27/16 09:29:04 AM
#16782   ok I've read that is that good for Lucky Fellow 05/26/17 09:17:26 AM
#16781   From the last filing regarding the warrants. The securities at14tao 05/25/17 08:38:50 PM
#16780   Its all about these warrants.... Hoping once they Lucky Fellow 05/25/17 07:00:16 PM
#16779   I've never felt so short but remain LONG medhead 05/25/17 11:29:20 AM
#16778   I think a nice squeeze is shaping up presley1000 05/25/17 10:58:18 AM
#16777   It almost seems like a big chunk of MasterBidder 05/25/17 09:19:17 AM
#16776   Short report is out. presley1000 05/24/17 08:23:15 PM
#16775   Amen brother! stockman69 05/23/17 08:05:55 AM
#16774   Over 900,000 shorts now. Throw us some big HNB57 05/22/17 09:44:50 PM
#16773   well L2 certainly is thin, CDEL and VNDM stockman69 05/22/17 09:44:43 AM
#16772   Why would anyone with less than 50,000 shares medhead 05/21/17 12:21:19 PM
#16771   More there than you may think. Licensing agreements medhead 05/21/17 12:15:41 PM
#16770   heres the link to the video mook806 05/21/17 09:04:04 AM
#16769   Good Day more like it $LXRP! BMoney386 05/19/17 04:07:49 PM
#16768   MM's finally letting up here? stockman69 05/19/17 12:46:29 PM
#16767   Noted! dangerx 05/19/17 12:37:45 PM
#16766   Good time to load up. medhead 05/19/17 11:23:53 AM
#16765   Well just scooped up more just now. Now Cabocat 05/19/17 11:12:38 AM
#16764   looking very good today a little PotsandPans420 05/19/17 10:45:33 AM
#16763   How about news NOT converting warrants to cash? lol presley1000 05/19/17 10:32:51 AM
#16762   the only news we ever get these days stockman69 05/19/17 10:20:18 AM
#16761   Was just checking that out as well; love Fallingknife75 05/19/17 10:02:46 AM
#16760   Lexaria raises US$1M from Warrant ExerciseMay 19, 2017 OTC MasterBidder 05/19/17 09:37:58 AM
#16759   That would be nice.. need to buy while Lucky Fellow 05/18/17 10:06:29 PM
#16758   would love to see that. :) presley1000 05/18/17 05:24:52 PM
#16757   I've seen scenarios on other plays before where ProjectTurbo 05/18/17 04:02:46 PM
#16756   look back over the years when this board PotsandPans420 05/18/17 03:38:52 PM
#16755   look back over the years when this board PotsandPans420 05/18/17 03:38:51 PM
#16754   900k shares shorted from March 1 - May ProjectTurbo 05/18/17 03:36:59 PM
#16753   If short grows again it means warrant purchasers MasterBidder 05/18/17 02:17:38 PM
#16752   Its time to start buying again, this price Jay Dills 05/18/17 02:09:48 PM
#16751   NEWS OUT: Lexaria Featured on Television MasterBidder 05/18/17 11:21:48 AM
#16750   Lets hope so codfather. This could be a deelong 05/18/17 10:39:59 AM
#16749   I wonder if there is immediate opportunities with MasterBidder 05/18/17 10:25:16 AM
#16748   Lets hope they get someone with a bit codfather 05/18/17 10:24:22 AM
#16747   Lexaria to be featured on BNN , there mook806 05/18/17 10:20:46 AM
#16746   I agree with you on the press releases... Lucky Fellow 05/18/17 09:53:21 AM
#16745   I think everyone just needs to relax a mook806 05/18/17 09:50:36 AM
#16744   I'm with you too, I have locked BMoney386 05/18/17 09:36:37 AM
#16743   Im with you- I have been thinking that deelong 05/18/17 09:22:14 AM
#16742   If they don't campaign hard around R&D results MasterBidder 05/18/17 09:01:39 AM
#16741   They might not want one.. they are going Lucky Fellow 05/17/17 07:04:52 PM
#16740   do they have an IR firm on board codfather 05/17/17 03:31:29 PM
#16739   The narrative created through communications/public relations is the MasterBidder 05/17/17 02:57:18 PM
#16738   nice to see, too bad someone taking another stockman69 05/17/17 01:50:12 PM
#16737   Patent published in Europe MasterBidder 05/17/17 01:07:34 PM
#16736   for what ever reason LXRP pps has always codfather 05/17/17 11:38:29 AM
#16735   I've searched. All I could find was a MasterBidder 05/17/17 10:37:16 AM
#16734   Is our pps ever gonna go back up BMoney386 05/17/17 10:00:37 AM
#16733   Anyone know who Adam Mogil is? presley1000 05/17/17 08:32:11 AM